A skin-depth analysis of integrins: Role of the integrin network in health and disease

Cell Communication and Adhesion

Volumn 20, Issue 6, 2013, Pages 155-169

  Hegde, Samarth ^a   Raghavan, Srikala ^a  

^a TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

Adhesion; Blistering diseases; Cancer; Integrins; Signaling; Skin; Therapeutics

Indexed keywords

ABCIXIMAB; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CILENGITIDE; COLLAGEN TYPE 17; COLLAGEN TYPE 7; DACARBAZINE; ENDOSTATIN; EPTIFIBATIDE; FIBRINOGEN; FLUCICLATIDE F 18; GALACTO ARGINYLGLYCYLASPARTIC ACID F 18; GRANULOCYTE COLONY STIMULATING FACTOR; HP 802 247; INTEGRIN; INTEGRIN LINKED KINASE; INTEGRIN RECEPTOR; JSM 6427; LAMININ; PACLITAXEL; PLECTIN; RADIOPHARMACEUTICAL AGENT; SIMVASTATIN; SMALL INTERFERING RNA; TIROFIBAN; TUMSTATIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VOLOCIXIMAB;

ANGIOGENESIS; BASEMENT MEMBRANE; BLISTER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CARCINOMA; CELL ADHESION; DERMIS; DEVELOPMENT; EPIDERMIS; EPIDERMOLYSIS BULLOSA; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EXTRACELLULAR MATRIX; GENE THERAPY; GLIOBLASTOMA; HEMIDESMOSOME; HOMEOSTASIS; HUMAN; KERATINOCYTE; LIGAND BINDING; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; MECHANICAL STRESS; MELANOMA; METASTATIC MELANOMA; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; SKIN; SKIN CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; WNT SIGNALING PATHWAY;

ANIMALS; CELL ADHESION; EPIDERMIS; EXTRACELLULAR MATRIX; HEMIDESMOSOMES; INTEGRINS; SKIN; SKIN DISEASES; SKIN NEOPLASMS;

EID: 84890354799     PISSN: 15419061     EISSN: 15435180     Source Type: Journal    
DOI: 10.3109/15419061.2013.854334     Document Type: Review

References (127)

1. Alghisi GC, Ponsonnet L, Ruegg C (2009). The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One. 4: E4449
2. Aoudjit F, Vuori K (2012). Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012: 283181
3. Avraamides CJ, Garmy-Susini B, Varner JA (2008). Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 8 : 604-617
4. Bandyopadhyay A, Rothschild G, Kim S, Calderwood DA, Raghavan S (2012). Functional differences between kindlin-1 and kindlin-2 in keratinocytes. J Cell Sci. 125: 2172-2184
5. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM (2005). Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defi nes a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 115: 339-347
6. Blanpain C, Fuchs E (2009). Epidermal homeostasis: A balancing act of stem cells in the skin. Nat Rev Mol Cell Biol. 10 : 207-217
7. Bouvard D, Pouwels J, De Franceschi N, Ivaska J (2013). Integrin inactivators: Balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol. 14: 430-442
8. Brakebusch C, Grose R, Quondamatteo F, Ramirez A, Jorcano JL, Pirro A, Svensson M, Herken R, Sasaki T, Timpl R, Werner S, F ä ssler R (2000). Skin and hair follicle integrity is crucially dependent on beta 1 integrin expression on keratinocytes. EMBO J. 19: 3990-4003
9. Bruckner-Tuderman L, Has C (2013). Disorders of the cutaneous basement membrane zone-The paradigm of epidermolysis bullosa. Matrix Biol. (Epub ahead of print
10. Cagnet S, Faraldo MM, Kreft M, Sonnenberg A, Raymond K, Glukhova MA (2013). Signaling events mediated by alpha3beta1 integrin are essential for mammary tumorigenesis. Oncogene. (Epub ahead of print
11. Calderwood DA, Campbell ID, Critchley DR (2013). Talins and kindlins: Partners in integrin-mediated adhesion. Nat Rev Mol Cell Biol. 14: 503-517
12. Cao Q, Cai W, Li T, Yang Y, Chen K, Xing L, Chen X (2006). Combination of integrin siRNA and irradiation for breast cancer therapy. Biochem Biophys Res Commun. 351 : 726-732
13. Carroll JM, Romero MR, Watt FM (1995). Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell. 83: 957-968
14. Charlesworth A, Gagnoux-Palacios L, Bonduelle M, Ortonne JP, De Raeve L, Meneguzzi G (2003). Identifi cation of a lethal form of epidermolysis bullosa simplex associated with a homozygous genetic mutation in plectin. J Invest Dermatol. 121: 1344-1348
15. Chen K, Tu Y, Zhang Y, Blair HC, Zhang L, Wu C (2008). PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells. J Biol Chem. 283: 2508-2517
16. Chometon G, Zhang ZG, Rubinstein E, Boucheix C, Mauch C, Aumailley M (2006). Dissociation of the complex between CD151 and laminin-binding integrins permits migration of epithelial cells. Exp Cell Res. 312: 983-995
17. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB (2006). Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer. 94: 1621-1626
18. Conget P, Rodriguez F, Kramer S, Allers C, Simon V, Palisson F, Gonzalez S, Yubero MJ (2010). Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 12: 429-431
19. Crampton SP, Wu B, Park EJ, Kim JH, Solomon C, Waterman ML, Hughes CC (2009). Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. PLoS One. 4: E7841
20. D'Alessandro M, Morley SM, Ogden PH, Liovic M, Porter RM, Lane EB (2004). Functional improvement of mutant keratin cells on addition of desmin: An alternative approach to gene therapy for dominant diseases. Gene Ther. 11: 1290-1295
21. Deng X, Li Q, Hoff J, Novak M, Yang H, Jin H, Erfani SF, Sharma C, Zhou P, Rabinovitz I, Sonnenberg A, Yi Y, Zhou P, Stipp CS, Kaetzel DM, Hemler ME, Yang XH (2012). Integrin-Associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia. 14: 678-689
22. Desgrosellier JS, Cheresh DA (2010). Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 10: 9-22
23. Devbhandari RP, Shi GM, Ke AW, Wu FZ, Huang XY, Wang XY, Shi YH, Ding ZB, Xu Y, Dai Z, Fan J, Zhou J (2011). Profi ling of the tetraspanin CD151 web and conspiracy of CD151/integrin beta1 complex in the progression of hepatocellular carcinoma. PLoS One. 6: E24901
24. Dougherty GW, Jose C, Gimona M, Cutler ML (2008). The Rsu-1-PINCH1-ILK complex is regulated by Ras activation in tumor cells. Eur J Cell Biol. 87: 721-734
25. Duffy MJ (2002). Urokinase-Type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem Soc Trans. 30: 207-210
26. Eliceiri BP, Cheresh DA (2001). Adhesion events in angiogenesis. Curr Opin Cell Biol. 13: 563-568
27. Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA, Mellerio JE, Murrell DF, Shimizu H, Uitto J, Vahlquist A, Woodley D, Zambruno G (2008). The classifi cation of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classifi cation of EB. J Am Acad Dermatol. 58: 931-950
28. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C (2009). Epidermolysis bullosa and the risk of life-Threatening cancers: The National EB Registry experience, 1986-2006. J Am Acad Dermatol. 60: 203-211
29. Fuchs E, Raghavan S (2002). Getting under the skin of epidermal morphogenesis. Nat Rev Genet. 3: 199-209
30. Gawecka JE, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Heikkila MM, Matter ML, Ramos JW (2012). RSK2 protein suppresses integrin activation and fi bronectin matrix assembly and promotes cell migration. J Biol Chem. 287 : 43424-43437
31. Giancotti FG, Ruoslahti E (1990). Elevated levels of the alpha 5 beta 1 fi bronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell. 60: 849-859
32. Gozgit JM, Pentecost BT, Marconi SA, Otis CN, Wu C, Arcaro KF (2006). Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. Mol Cancer Res. 4: 905-913
33. Guo L, Degenstein L, Dowling J, Yu QC, Wollmann R, Perman B, Fuchs E (1995). Gene targeting of BPAG1: Abnormalities in mechanical strength and cell migration in stratifi ed epithelia and neurologic degeneration. Cell. 81: 233-243
34. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG (2006). Beta 4 integrin amplifi es ErbB2 signaling to promote mammary tumorigenesis. Cell. 126: 489-502
35. Has C, Sparta G, Kiritsi D, Weibel L, Moeller A, Vega-Warner V, Waters A, He Y, Anikster Y, Esser P, Straub BK, Hausser I, Bockenhauer D, Dekel B, Hildebrandt F, Bruckner-Tuderman L, Laube GF (2012). Integrin alpha3 mutations with kidney, lung, and skin disease. N Engl J Med. 366: 1508-1514
36. Heinemann A, He Y, Zimina E, Boerries M, Busch H, Chmel N, Kurz T, Bruckner-Tuderman L, Has C (2011). Induction of phenotype modifying cytokines by FERMT1 mutations. Hum Mutat. 32: 397-406
37. Herz C, Aumailley M, Schulte C, Schlotzer-Schrehardt U, Bruckner-Tuderman L, Has C (2006). Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes. J Biol Chem. 281: 36082-36090
38. Hynes RO (2002). Integrins: Bidirectional, allosteric signaling machines. Cell. 110: 673-687
39. Itoh M, Kiuru M, Cairo MS, Christiano AM (2011). Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 108: 8797-8802
40. Janes SM, Watt FM (2006). New roles for integrins in squamouscell carcinoma. Nat Rev Cancer. 6: 175-183
41. Karamatic Crew V, Burton N, Kagan A, Green CA, Levene C, Flinter F, Brady RL, Daniels G, Anstee DJ (2004). CD151, the fi rst member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin. Blood. 104: 2217-2223
42. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Donate F, Shaw DE, Mazar AP, Rabbani SA (2006). A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 5 : 2271-2280
43. Kiema T, Lad Y, Jiang P, Oxley CL, Baldassarre M, Wegener KL, Campbell ID, Ylanne J, Calderwood DA (2006). The molecular basis of fi lamin binding to integrins and competition with talin. Mol Cell. 21: 337-347
44. Kiuru M, Itoh M, Cairo MS, Christiano AM (2010). Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin. 28: 371-382, xii-xiii
45. Kloeker S, Major MB, Calderwood DA, Ginsberg MH, Jones DA, Beckerle MC (2004). The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. J Biol Chem. 279: 6824-6833
46. Kogelberg H, Tolner B, Thomas GJ, Di Cara D, Minogue S, Ramesh B, Sodha S, Marsh D, Lowdell MW, Meyer T, Begent RH, Hart I, Marshall JF, Chester K (2008). Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specifi city-determining loop of a foot-And-mouth disease virus. J Mol Biol. 382: 385-401
47. Kogelberg H, Miranda E, Burnet J, Ellison D, Tolner B, Foster J, Picon C, Thomas GJ, Meyer T, Marshall JF, Mather SJ, Chester K (2013). Generation and Characterization of a Diabody Targeting the alphavbeta6 Integrin. PLoS One. 8: E73260
48. Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Nam SJ, Im YH, Shin YK, Choi YL (2012). Clinical signifi cance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer. 106: 923-930
49. Lai-Cheong JE, Ussar S, Arita K, Hart IR, McGrath JA (2008). Colocalization of kindlin-1, kindlin-2, and migfi lin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J Invest Dermatol. 128: 2156-2165
50. Lai-Cheong JE, Tanaka A, Hawche G, Emanuel P, Maari C, Taskesen M, Akdeniz S, Liu L, McGrath JA (2009). Kindler syndrome: A focal adhesion genodermatosis. Br J Dermatol. 160: 233-242
51. Lai-Cheong JE, Parsons M, McGrath JA (2010). The role of kindlins in cell biology and relevance to human disease. Int J Biochem Cell Biol. 42: 595-603
52. Laimer M, Lanschuetzer CM, Diem A, Bauer JW (2010). Herlitz junctional epidermolysis bullosa. Dermatol Clin. 28: 55-60
53. Legate KR, Montanez E, Kudlacek O, Fassler R (2006). ILK, PINCH and parvin: The tIPP of integrin signalling. Nat Rev Mol Cell Biol. 7: 20-31
54. Li J, Tan H, Dong X, Xu Z, Shi C, Han X, Jiang H, Krissansen GW, Sun X (2007). Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig Liver Dis. 39: 557-565
55. Li Q, Li C, Zhang YY, Chen W, Lv JL, Sun J, You QS (2013). Silencing of integrin-linked kinase suppresses in vivo tumorigenesis of human ovarian carcinoma cells. Mol Med Rep. 7: 1050-1054
56. Liang F, Zhang S, Wang B, Qiu J, Wang Y (2013). Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-kappaB pathway. J Mol Histol. (Epub ahead of print
57. Liao Y, Itoh M, Yang A, Zhu H, Roberts S, Highet AM, Latshaw S, Mitchell K, van de Ven C, Christiano A, Cairo MS (2013). Human cord blood derived unrestricted somatic stem cells promote wound healing and have therapeutic potential for patients with recessive dystrophic epidermolysis bullosa. Cell Transplant. (Epub ahead of print
58. Lim S, Kawamura E, Fielding AB, Maydan M, Dedhar S (2013). Integrin-linked kinase regulates interphase and mitotic microtubule dynamics. PLoS One. 8: E53702
59. Liu Q, Xiao L, Yuan D, Shi X, Li P (2012). Silencing of the integrin-linked kinase gene induces the apoptosis in ovarian carcinoma. J Recept Signal Transduct Res. 32: 120-127
60. Lorenz K, Grashoff C, Torka R, Sakai T, Langbein L, Bloch W, Aumailley M, Fassler R (2007). Integrin-linked kinase is required for epidermal and hair follicle morphogenesis. J Cell Biol. 177: 501-513
61. Macias-Perez I, Borza C, Chen X, Yan X, Ibanez R, Mernaugh G, Matrisian LM, Zent R, Pozzi A (2008). Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. Cancer Res. 68: 6127-6135
62. Margadant C, Charafeddine RA, Sonnenberg A (2010). Unique and redundant functions of integrins in the epidermis. FASEB J. 24: 4133-4152
63. Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, Maruggi G, Ferrari G, Provasi E, Bonini C, Capurro S, Conti A, Magnoni C, Giannetti A, De Luca M (2006). Correction of junctional epidermolysis bullosa by transplantation of genetically modifi ed epidermal stem cells. Nat Med. 12: 1397-1402
64. McCarty JH, Barry M, Crowley D, Bronson RT, Lacy-Hulbert A, Hynes RO (2008). Genetic ablation of alphav integrins in epithelial cells of the eyelid skin and conjunctiva leads to squamous cell carcinoma. Am J Pathol. 172: 1740-1747
65. Meerovitch K, Bergeron F, Leblond L, Grouix B, Poirier C, Bubenik M, Chan L, Gourdeau H, Bowlin T, Attardo G (2003). A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vascul Pharmacol. 40: 77-89
66. Millard M, Odde S, Neamati N (2011). Integrin targeted therapeutics. Theranostics. 1: 154-188
67. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM (1996). Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: Roles of integrin aggregation and occupancy of receptors. J Cell Biol. 135: 1633-1642
68. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R (2008). Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 14: 325-330
69. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. (2007). Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 25: 1651-1657
70. Nakrieko KA, Welch I, Dupuis H, Bryce D, Pajak A, St Arnaud R, Dedhar S, D'Souza SJ, Dagnino L (2008). Impaired hair follicle morphogenesis and polarized keratinocyte movement upon conditional inactivation of integrin-linked kinase in the epidermis. Mol Biol Cell. 19 : 1462-1473
71. Nasulewicz-Goldeman A, Uszczynska B, Szczaurska-Nowak K, Wietrzyk J (2012). siRNA-mediated silencing of integrin beta3 expression inhibits the metastatic potential of B16 melanoma cells. Oncol Rep. 28: 1567-1573
72. Nevo J, Mai A, Tuomi S, Pellinen T, Pentikainen OT, Heikkila P, Lundin J, Joensuu H, Bono P, Ivaska J (2010). Mammaryderived growth inhibitor (MDGI) interacts with integrin alpha-subunits and suppresses integrin activity and invasion. Oncogene. 29: 6452-6463
73. Ohmatsu H, Kadono T, Sugaya M, Tomita M, Kai H, Miyagaki T, Saeki H, Tamaki K, Steeber DA, Tedder TF, Sato S (2010). alpha4beta7 Integrin is essential for contact hypersensitivity by regulating migration of T cells to skin. J Allergy Clin Immunol. 126: 1267-1276
74. Olasz EB, Yancey KB (2008). Bullous pemphigoid and related subepidermal autoimmune blistering diseases. Curr Dir Autoimmun. 10: 141-166
75. Oloumi A, McPhee T, Dedhar S (2004). Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta. 1691: 1-15
76. Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, Blazar BR, Tolar J (2013). TALEN-based gene correction for epidermolysis bullosa. Mol Ther. 21: 1151-1159
77. Papanikolaou S, Bravou V, Gyftopoulos K, Nakas D, Repanti M, Papadaki H (2010). ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion. Histopathology. 56: 799-809
78. Pasmooij AM, Pas HH, Bolling MC, Jonkman MF (2007). Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J Clin Invest. 117: 1240-1248
79. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-infl ammatory target. Science. 319: 627-630
80. Perdih A, Dolenc MS (2010). Small molecule antagonists of integrin receptors. Curr Med Chem. 17: 2371-2392
81. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC (1999). Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 59: 2724-2730
82. Petrof G, Martinez-Queipo M, Mellerio JE, Kemp P, McGrath JA (2013). Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: Results of a randomised, vehicle-controlled trial. Br J Dermatol. (Epub ahead of print
83. Piwko-Czuchra A, Koegel H, Meyer H, Bauer M, Werner S, Brakebusch C, Fassler R (2009). Beta1 integrin-mediated adhesion signalling is essential for epidermal progenitor cell expansion. PLoS One. 4: E5488
84. Raghavan S, Bauer C, Mundschau G, Li Q, Fuchs E (2000). Conditional ablation of beta1 integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination. J Cell Biol. 150: 1149-1160
85. Rantala JK, Pouwels J, Pellinen T, Veltel S, Laasola P, Mattila E, Potter CS, Duffy T, Sundberg JP, Kallioniemi O, Askari JA, Humphries MJ, Parsons M, Salmi M, Ivaska J (2011). SHARPIN is an endogenous inhibitor of beta1-integrin activation. Nat Cell Biol. 13: 1315-1324
86. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB (2008). Randomized phase II study of cilengitide, an integrin-Targeting arginineglycine-Aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 26: 5610-5617
87. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K (2001). Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A. 98: 1024-1029
88. Remington J, Wang X, Hou Y, Zhou H, Burnett J, Muirhead T, Uitto J, Keene DR, Woodley DT, Chen M (2009). Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther. 17: 26-33
89. Robbins PB, Lin Q, Goodnough JB, Tian H, Chen X, Khavari PA (2001). In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci U S A. 98: 5193-5198
90. Sachs N, Kreft M, van den Bergh Weerman MA, Beynon AJ, Peters TA, Weening JJ, Sonnenberg A (2006). Kidney failure in mice lacking the tetraspanin CD151. J Cell Biol. 175 : 33-39
91. Saito D, Kyakumoto S, Chosa N, Ibi M, Takahashi N, Okubo N, Sawada S, Ishisaki A, Kamo M (2013). Transforming growth factor-beta1 induces epithelial-mesenchymal transition and integrin alpha3beta1-mediated cell migration of HSC-4 human squamous cell carcinoma cells through Slug. J Biochem. 153: 303-315
92. Samanna V, Wei H, Ego-Osuala D, Chellaiah MA (2006). Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res. 312: 2214-2230
93. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC (2004). Cancer siRNA therapy by tumor selective delivery with ligand-Targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32: E149
94. Shi X, Wu C (2008). A suppressive role of mitogen inducible gene-2 in mesenchymal cancer cell invasion. Mol Cancer Res. 6: 715-724
95. Shinkuma S, McMillan JR, Shimizu H (2011). Ultrastructure and molecular pathogenesis of epidermolysis bullosa. Clin Dermatol. 29: 412-419
96. Siegel DH, Ashton GH, Penagos HG, Lee JV, Feiler HS, Wilhelmsen KC, South AP, Smith FJ, Prescott AR, Wessagowit V, Oyama N, Akiyama M, Al Aboud D, Al Aboud K, Al Githami A, Al Hawsawi K, Al Ismaily A, Al-Suwaid R, Atherton DJ, Caputo R, Fine JD, Frieden IJ, Fuchs E, Haber RM, Harada T, Kitajima Y, Mallory SB, Ogawa H, Sahin S, Shimizu H, Suga Y, Tadini G, Tsuchiya K, Wiebe CB, Wojnarowska F, Zaghloul AB, Hamada T, Mallipeddi R, Eady RA, McLean WH, McGrath JA, Epstein EH (2003). Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet. 73: 174-187
97. Smith FJ, Eady RA, Leigh IM, McMillan JR, Rugg EL, Kelsell DP, Bryant SP, Spurr NK, Geddes JF, Kirtschig G, Milana G, de Bono AG, Owaribe K, Wiche G, Pulkkinen L, Uitto J, McLean WH, Lane EB (1996). Plectin defi ciency results in muscular dystrophy with epidermolysis bullosa. Nat Genet. 13: 450-457
98. Stanchi F, Grashoff C, Nguemeni Yonga CF, Grall D, Fassler R, Van Obberghen-Schilling E (2009). Molecular dissection of the ILK-PINCH-parvin triad reveals a fundamental role for the ILK kinase domain in the late stages of focal-Adhesion maturation. J Cell Sci. 122: 1800-1811
99. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA (2001). Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 155: 459-470
100. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 28: 2712-2718
101. Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley SJ, Hemler ME (2011). Diminished metastasis in tetraspanin CD151-knockout mice. Blood. 118: 464-472
102. Timpl R, Brown JC (1996). Supramolecular assembly of basement membranes. Bioessays. 18: 123-132
103. Tolar J, Xia L, Riddle MJ, Lees CJ, Eide CR, McElmurry RT, Titeux M, Osborn MJ, Lund TC, Hovnanian A, Wagner JE, Blazar BR (2011). Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 131: 848-856
104. Tolar J, Xia L, Lees CJ, Riddle M, McElroy A, Keene DR, Lund TC, Osborn MJ, Marinkovich MP, Blazar BR, Wagner JE (2013). Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa. J Invest Dermatol. 133: 562-565
105. Ussar S, Moser M, Widmaier M, Rognoni E, Harrer C, Genzel-Boroviczeny O, Fassler R (2008). Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet. 4: E1000289
106. Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM (2008). Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res. 68: 561-570
107. Varner JA, Emerson DA, Juliano RL (1995). Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fi bronectin. Mol Biol Cell. 6: 725-740
108. Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 363: 629-639
109. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL (2009). Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res. 69 : 475-482
110. Watt FM (2002). Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J. 21: 3919-3926
111. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, Campbell ID (2007). Structural basis of integrin activation by talin. Cell. 128: 171-182
112. Weinstein EJ, Bourner M, Head R, Zakeri H, Bauer C, Mazzarella R (2003). URP1: A member of a novel family of PH and FERM domain-containing membrane-Associated proteins is signifi cantly over-expressed in lung and colon carcinomas. Biochim Biophys Acta. 1637: 207-216
113. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 6 : 159-170
114. White SJ, McLean WH (2005). Kindler surprise: Mutations in a novel actin-Associated protein cause Kindler syndrome. J Dermatol Sci. 38: 169-175
115. Wickstrom SA, Lange A, Montanez E, Fassler R (2010). The ILK/PINCH/parvin complex: The kinase is dead, long live the pseudokinase! EMBO J 29: 281-291
116. Wickstrom SA, Radovanac K, Fassler R (2011). Genetic analyses of integrin signaling. Cold Spring Harb Perspect Biol. 3
117. Wolfenson H, Lavelin I, Geiger B (2013). Dynamic regulation of the structure and functions of integrin adhesions. Dev Cell. 24: 447-458
118. Wright MD, Geary SM, Fitter S, Moseley GW, Lau LM, Sheng KC, Apostolopoulos V, Stanley EG, Jackson DE, Ashman LK (2004). Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol. 24 : 5978-5988
119. Wu C (2004). The PINCH-ILK-parvin complexes: Assembly, functions and regulation. Biochim Biophys Acta. 1692: 55-62
120. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE (2006). Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery. 59: 1304-1312 ; discussion 1312
121. Yancey KB, Hintner H (2010). Non-herlitz junctional epidermolysis bullosa. Dermatol Clin. 28: 67-77
122. Yu Y, Wu J, Wang Y, Zhao T, Ma B, Liu Y, Fang W, Zhu WG, Zhang H (2012). Kindlin 2 forms a transcriptional complex with beta-catenin and TCF4 to enhance Wnt signalling. EMBO Rep. 13: 750-758
123. Zevian S, Winterwood NE, Stipp CS (2011). Structure-function analysis of tetraspanin CD151 reveals distinct requirements for tumor cell behaviors mediated by alpha3beta1 versus alpha6beta4 integrin. J Biol Chem. 286: 7496-7506
124. Zhao H, Ross FP, Teitelbaum SL (2005). Unoccupied alpha(v) beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol Endocrinol. 19: 771-780
125. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P (2007). Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 67: 5821-5830
126. Zhu CQ, Popova SN, Brown ER, Barsyte-Lovejoy D, Navab R, Shih W, Li M, Lu M, Jurisica I, Penn LZ, Gullberg D, Tsao MS (2007). Integrin alpha 11 regulates IGF2 expression in fi broblasts to enhance tumorigenicity of human nonsmall-cell lung cancer cells. Proc Natl Acad Sci U S A. 104 : 11754-11759
127. Zhu XY, Liu N, Liu W, Song SW, Guo KJ (2012). Silencing of the integrin-linked kinase gene suppresses the proliferation, migration and invasion of pancreatic cancer cells (Panc-1). Genet Mol Biol. 35: 538-544